Shen-Hong-Tong-Luo formula ameliorates atherosclerosis by enhancing macrophage efferocytosis through activating the PPARγ/mfge8 pathway

Read full text
Authors: Yanyu Shi, Zepeng Zhang, Jiaqi Liu, Xiaolin Xu, Xue Xiao, Tianyang Zhang, Yuan Zhang, Haoran Cui, Xiangyan Li, Ying Chen
Cited by: 1
References: 40

Abstract

Background Atherosclerosis (AS) is a chronic inflammatory disorder driven by dysregulated lipid metabolism and remains a leading cause of cardiovascular morbidity. The Shen−Hong−Tong−Luo (SHTL) preparation has demonstrated clinical benefit in stabilizing atherosclerotic plaques, yet its molecular mechanisms are not fully defined. Purpose This research sought to elucidate the protective effects exerted by SHTL on AS progression. Methods To investigate the impact of SHTL on macrophage function and plaque stability, we utilized ApoE -/- mice models and bone marrow-derived macrophages (BMDMs) stimulated with lipopolysaccharide (LPS) and oxidized low-density lipoprotein (Ox-LDL). Network pharmacological analysis was conducted to predict potential therapeutic targets of SHTL, with a particular focus on the efferocytosis pathway. These predictions were subsequently confirmed by immunofluorescence (IF) staining and flow cytometry experiments performed on ApoE -/- mice and BMDMs. Furthermore, using data-independent acquisition (DIA) proteomics, milk fat globule-epidermal growth factor 8 (Mfge8) was identified as a critical factor facilitating SHTL-enhanced efferocytosis. Chip-PCR and GW9662 were applied to explore the involvement of peroxisome proliferator-activated receptor gamma (PPARγ) signaling. Results SHTL markedly attenuated the progression of AS, demonstrated by reduced plaque formation within both the aortic root and aorta, diminished plasma lipid concentrations, and suppressed inflammatory responses. In vitro assays using BMDMs revealed that SHTL significantly inhibited foam cell formation and inflammation induced by Ox-LDL and LPS. Furthermore, SHTL enhanced efferocytosis both in vivo and in vitro by upregulating Mfge8 expression. Treatment with GW9662 abolished these beneficial effects, confirming that SHTL exerts its protective actions via activation of the PPARγ/Mfge8 pathway. Conclusion SHTL demonstrates significant anti-inflammatory and lipid-regulatory effects, attenuating AS progression through the PPARγ/Mfge8 pathway, thereby enhancing macrophage efferocytosis. These findings highlight a novel mechanism by which SHTL may contribute to preventing and treating atherosclerotic diseases.

Fields of Study & Subjects

Phagocytosis and Immune Regulation Immune cells in cancer Atherosclerosis and Cardiovascular Diseases

Publication details

Journal / source
Frontiers in Immunology
Publisher
Frontiers Media SA
Volume
16
Pages
1727378–1727378
Publication date
20 January 2026
Language
EN